DNA Sequencing: Emerging Technologies and Applications

Report Highlights

The global market for sequencing products and services reached $3.5 billion in 2012. This market is expected to grow to nearly $4.5 billion in 2013 and nearly 11.7 billion in 2018, a compound annual growth rate (CAGR) of 21.2%.

Report Includes

• An overview of the global market for sequencing products and services.
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Quantification of the DNA sequencing markets by product type, platform, customer type,value chain position, analysis type and geography.
• A look at substantial future growth opportunities for industry participants including consumer and diagnostic sequencing services, bioinformatics, sequence enrichment, benchtop NGS sequencers and consumables, and emerging sequencing instruments.

Report Scope

The scope of the report includes sequencing technologies, applications, industries, initiatives, markets, patents and companies. The markets for sequencing products and services are given for the years 2012, 2013 and 2018.

This report reviews the main sequencing platforms, and explains why genetic variation is important for many markets, including clinical testing. It then discusses some of the top research initiatives that are contributing to NGS applications. Market driving forces are also discussed.

The report covers the sequencing markets by workflow, including sample preparation products; sequencing instruments & consumables; informatics; and sequencing services. It includes the sequencing instrument market by platform: Sanger, NGS and 3GS and by instrument class: low throughput, high-throughput, benchtop, and handheld.

The report covers the markets for the main sequencing end use applications, including research (R&D, drug discovery & development, biotech); clinical; consumer; and applied (forensics, microbial genomics, agricultural genomics).

A key part of the report covers NGS clinical markets in depth, including by test complexity, indication and test purpose. Test complexity refers to the multiplexing (e.g., the number of genes covered) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics) will be in demand in the future.

The report provides market data and forecasts for NGS diagnostics by specific applications, including those for cancer, rare diseases, common diseases, and pre- and post-natal screening.

Specific geographic markets are discussed, including North America, Europe, China, Japan and the rest of the world.

Market data covers the years 2012, 2013 and 2018.

Industry sectors analyzed in this report include NGS instruments (including market share data for the main instrument companies); NGS target enrichment; 3GS; direct to consumer genetic testing; single cell genomics; NGS-based proteomics; informatics; information technology; clinical laboratory; and the prenatal diagnostics (including market shares for the leading NGS companies).

More than 142 companies in the sequencing industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from 2011 through 2013, including key alliance trends.

Analyst Credentials

John Bergin has produced successful and highly regarded market research reports in the life science industry for BCC research for more than 10 years. Mr. Bergin has held business development and international sales and marketing positions with Corning Inc., an advanced materials company. He has also held executive management positions with IBC Advanced Technologies, a molecular recognition company specializing in separations. Mr. Bergin's extensive expertise in commercializing new technologies is reflected in his market research reports.

Mr. Bergin received a BS degree in Chemistry and Masters of Business Administration (MBA) degree from Brigham Young University and an MS degree in biotechnology from Johns Hopkins University. John Bergin is a pseudonym of the author.